cyclosporine / Generic mfg. - LARVOL DELTA

Adverse and Serious Adverse Events Associated With Tocilizumab in COVID-19 Pneumonia and With Cyclosporin, Pazopanib, and Insulin Glargine in Other Diseases: A Single-Center Cross-Sectional Study From a Tertiary Care Center in Bangladesh. (PubMed, Cureus) - "The results reflect outcomes among reported SAEs; however, they should not be interpreted as statistically significant.  Conclusion This study highlights serious adverse outcomes associated with tocilizumab and other commonly used medications in real-world clinical practice. Although casualty cannot be established due to the limited sample size and observational design, the findings emphasize the importance of vigilant pharmacovigilance and cautious interpretation of treatment outcomes."

Adverse events • Journal • Observational data • Serious adverse event • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Five-year follow-up sustained remission with rituximab in a patient with focal segmental glomerulosclerosis: A case report. (PubMed, World J Nephrol) - "This case contributes to the growing evidence supporting rituximab's therapeutic potential in adult FSGS, while highlighting the need for randomized controlled trials to establish its efficacy and optimal use in this challenging patient population."

Journal • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Lupus Nephritis • Nephrology • Renal Disease

CUTANEOUS MANIFESTATIONS IN RENAL TRANSPLANT RECIPENTS: A SINGLE CENTER, CROSS-SECTIONAL STUDY IN THAILAND (ISN-WCN 2026) - "Immunosuppressive regimens included calcineurin inhibitors, azathioprine, mycophenolate mofetil/mycophenolic acid, cyclosporine, and prednisolone. Prednisolone dosages ≥ 20 mg/day correlated with significantly higher prevalence of herpes zoster (30% vs. 8%, p < 0.05), dermatophytes (20% vs. 4.8%, p < 0.05), pityrosporum folliculitis (50% vs. 5.6%, p < 0.001), and acneiform eruptions (50% vs. 5.6%, p < 0.001).Conclusion Skin conditions are prevalent in RTRs, particularly after the first-year post-transplant. Associations between graft rejection, high-dose prednisolone, and herpes zoster warrant further study."

Clinical • Observational data • Herpes Simplex • Herpes Zoster • Infectious Disease • Transplant Rejection • Transplantation • Varicella Zoster

PODOCYTE INFOLDING GLOMERULOPATHY ASSOCIATED WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE INITIALLY TREATED AS MINIMAL CHANGE NEPHROTIC SYNDROME (ISN-WCN 2026) - "After achieving remission (UPCR <0.3 g/gCr) in August 2022, prednisolone and cyclosporine were discontinued in February and July 2024, respectively...Induction therapy with prednisolone (50 mg/day, 1 mg/kg/day), mycophenolate mofetil (500 mg/day) and hydroxychloroquine (200 mg/day) was initiated, followed by tacrolimus (2 mg/day) because of persistent nephrotic-range proteinuria...Although no specific treatment for PIG exists, immunosuppressive therapy targeting underlying SLE improved proteinuria and abdominal symptoms. This case suggests that clinicians should re-examine renal pathology when NS follows an atypical course."

Clinical • Gastrointestinal Disorder • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Nephrology • Renal Disease • Systemic Lupus Erythematosus

A CASE OF IGA-ASSOCIATED MEMBRANOUS NEPHROPATHY WITH RECURRENT RELAPSES AND SUPERIMPOSED DIABETIC NEPHROPATHY: CLINICAL COURSE, PATHOLOGY, AND RESPONSE TO IMMUNOSUPPRESSION. (ISN-WCN 2026) - "After the kidney biopsy, steroid was adjusted as needed and controlled around 1 g/gCr, but since it gradually became resistant to treatment, cyclosporine was added, resulting in remission and allowing steroid reduction.Conclusion In this case, IgA-MN showed pathological features distinct from typical IgG-MN, including relatively small subepithelial electron-dense deposits and marked podocyte infolding on electron microscopy...Mass spectrometry suggested that different proteins, and potentially their corresponding autoantibodies, may contribute to IgA-MN pathogenesis. Many aspects remain unclear, and further detailed studies are needed."

Clinical • Bladder Cancer • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Genito-urinary Cancer • Glomerulonephritis • Metabolic Disorders • Nephrology • Renal Disease • Solid Tumor

COMPARATIVE ANALYSIS BETWEEN PEDIATRIC AND ADULT KIDNEY TRANSPLANT RECIPIENTS: A MULTICENTRIC RETROSPECTIVE STUDY (ISN-WCN 2026) - "As for maintenance therapy, all pediatric patients received steroids, and they were more frequently treated with azathioprine (12.5% vs 0.3%, p < 0.001) and cyclosporine (6.7% vs 0.6%, p < 0.001), whereas mTOR inhibitors were used exclusively in adults (25.2% vs 0%, p < 0.001). Mycophenolate mofetil was slightly more common in pediatric patients (86.5% vs 76.2%, p = 0.025)...Despite distinct immunological and clinical differences, graft survival, rejection rates, and disease recurrence were comparable between groups. Based on our results, future clinical trials should include pediatric cohorts to ensure equitable treatment across all age groups."

Retrospective data • Infectious Disease • Nephrology • Pediatrics • Transplantation

CAPLACIZUMAB IS EFFECTIVE IN ACHIEVING EARLY PLATELET RECOVERY AND MAINTAINING STABILITY IN IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA WITH POST–PLASMA EXCHANGE REBOUND OF ANTI-ADAMTS13 ANTIBODIES: CASE SERIES (ISN-WCN 2026) - "All patients received PE (1.1–1.5 plasma volumes per session, replaced with fresh-frozen plasma), prednisolone, rituximab, and caplacizumab. P5 additionally received cyclosporine, and P6 received cyclophosphamide...These observations suggest that, in addition to platelet count, serial monitoring of ADAMTS13 activity and inhibitor titers is critical for assessing disease activity. Caplacizumab may help maintain platelet count stability during transient inhibitor rebound, but careful immunologic follow-up is warranted to guide treatment optimization."

Clinical • Hematological Disorders • Thrombocytopenic Purpura

MINIMAL CHANGE DISEASE AS A PARANEOPLASTIC MANIFESTATION OF BRCA1 MUTATION–POSITIVE FALLOPIAN TUBE CANCER: AN AUTOPSY CASE (ISN-WCN 2026) - "She received intravenous methylprednisolone (1 g/day for 3 days), followed by oral prednisolone (40 mg/day) and cyclosporine (100 mg/day).Results Despite combined corticosteroid and immunosuppressive therapy, nephrotic-range proteinuria persisted, and serum albumin levels remained markedly low. Genetic testing and risk-reducing salpingo-oophorectomy (RRSO) may help prevent such outcomes in BRCA1 mutation carriers. Early oncologic evaluation is essential when nephrotic syndrome fails to respond to standard immunosuppressive therapy."

Clinical • Breast Cancer • Congestive Heart Failure • Fallopian Tube Cancer • Glomerulonephritis • Gynecology • Heart Failure • Hematological Malignancies • Lymphoma • Oncology • Ovarian Cancer • Respiratory Diseases • BRCA1

GRANULOMATOUS INTERSTITIAL NEPHRITIS: COULD IT BE TUBERCULOSIS? (ISN-WCN 2026) - "While destructive urinary tuberculosis is a well described condition, there has been a growing number of tuberculous GIN of unclear mechanism, without bacteriologic evidence.Methods We describe a 28-year-old female patient, a laboratory technician in a mycobacteriology laboratory, with a history of untreated asymptomatic Crohn disease who presented with AKI without proteinuria.Results The patient had a history of Mesalazine and cyclosporine treatment for Crohn disease, stopped for 3 years at the time of the AKI...Finally, the IGRA, which was initially uncertain, became positive after starting anti-TNF treatment, with further deterioration in renal function. The diagnosis of tuberculosis is presumed given the improvement in renal function after anti-tuberculosis treatment and stability after discontinuation of corticosteroid therapy.More studies are needed to explore the mechanisms of tuberculous GIN."

Crohn's disease • Gastroenterology • Genetic Disorders • Glomerulonephritis • Gynecology • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Nephrology • Respiratory Diseases • Sarcoidosis • Tuberculosis

PGNMID WITH AKI SUCCESSFULLY MANAGED BY CLONE-DIRECTED THERAPY (ISN-WCN 2026) - "We report a case of PGNMID with severe AKI requiring hemodialysis following recovery from infectious enteritis, successfully managed by clone-directed therapy, including daratumumab and bortezomib.Methods A 60-year-old man presented with proteinuria and edema...He was treated with steroid pulse therapy followed by oral prednisolone and an ARB, later combined with cyclosporine and an SGLT2 inhibitor, achieving partial remission...Prospective studies are essential to establish optimal treatment strategies for PGNMID with AKI. The current case indicates that the narrowing of the glomerular capillary lumina, resulting from an increase in inflammatory cells and mesangial matrix expansion, may lead to AKI."

Gastrointestinal Disorder • Glomerulonephritis • Infectious Disease • Lupus Nephritis • Nephrology • Novel Coronavirus Disease • Renal Disease

EFFICACY OF LDL APHERESIS IN INDUCING REMISSION IN REFRACTORY MINIMAL CHANGE NEPHROTIC SYNDROME: A CASE SERIES OF FOUR PATIENTS (ISN-WCN 2026) - "Case 2: A 74-year-old woman with recurrent MCNS relapsed despite prednisolone and cyclosporine...Broader application of LDL-A, potentially including newer centrifugal systems, may enhance global accessibility. Larger prospective studies are warranted to define its optimal use in MCNS."

Clinical • Chronic Kidney Disease • Diabetes • Dyslipidemia • Familial Hypercholesterolemia • Focal Segmental Glomerulosclerosis • Genetic Disorders • Glomerulonephritis • Metabolic Disorders • Nephrology • Renal Disease

CALCINEURIN INHIBITOR THERAPY AND CLINICAL RESPONSE IN WT1-RELATED DISORDERS (ISN-WCN 2026) - "The CNI users included 14 patients on cyclosporine and 2 patients on tacrolimus...This study represents one of the largest multi-institutional cohorts of WT1-related disorders analyzed to date. These findings provide descriptive data on treatment patterns and outcomes, and further studies are required to determine the long-term clinical significance of CNI use."

Clinical • Glomerulonephritis • Nephrology • Renal Disease • Solid Tumor • Wilms Tumor • WT1

PLASMA CELL-RICH ACUTE REJECTION IN A YOUNG KIDNEY TRANSPLANT PATIENT AND THE ROLE OF ANTI-CD38 THERAPY (ISN-WCN 2026) - "The maintenance immunosuppressive regimen consisted of cyclosporine, mycophenolate mofetil, and corticosteroids.Five years later, she developed acute kidney injury (creatinine 2.8 mg/dL), accompanied by sub-nephrotic proteinuria (1.5 g/24h), and microhematuria. Our experience suggests that daratumumab may offer a promising therapeutic option to reduce plasma cell infiltration and improve graft outcomes. Further studies are needed to confirm its efficacy and define optimal protocols."

Clinical • IO biomarker • Acute Kidney Injury • Antibody-mediated Rejection • Genetic Disorders • Nephrology • Transplant Rejection • Transplantation

CYCLOSPORINE-INDUCED REMISSION IN PEDIATRIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ANTI-NEPHRIN AUTOANTIBODY POSITIVITY (ISN-WCN 2026) - "Re-submission of this work has been permitted by the meeting organizers.Conflict of Interest statement:The authors declare no conflicts of interest relevant to this work.AI statement:Artificial intelligence (AI)–assisted technology (ChatGPT, OpenAI) was used to refine the English language and improve the clarity of this abstract. All content was reviewed and approved by the authors, who take full responsibility for the work."

Clinical • Chronic Kidney Disease • Dyslipidemia • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Metabolic Disorders • Pediatrics

DIVERSE PHENOTYPIC EXPRESSIONS OF COL4A4 MUTATIONS: A CASE OF NEPHROTIC SYNDROME PRESENTING AS FSGS (ISN-WCN 2026) - "Cyclosporine was added, and low-density lipoprotein (LDL) apheresis was performed four times; however, proteinuria persisted...Taken together, these cases underscore the clinical heterogeneity and complexity of type Ⅳ collagen-associated kidney disease.Conclusion Even in adult-onset, treatment-resistant FSGS, genetic testing including COL4A3-COL4A5 can provide diagnostic and prognostic insight. Recognizing the broader clinical spectrum of COL4-related nephropathy may improve patient management and genetic counseling."

Clinical • Cardiovascular • Chronic Kidney Disease • Dyslipidemia • Focal Segmental Glomerulosclerosis • Genetic Disorders • Glomerulonephritis • Hypertension • Nephrology • Renal Disease • COL4A5

SUCCESSFUL TREATMENT OF IMMUNOSUPPRESSIVE THERAPY AND LDL-APHERESIS FOR NEPHROTIC SYNDROME CAUSED BY FIBRONECTIN GLOMERULOPATHY DIAGNOSED BY IMMUNOSTAINING AND GENETIC ANALYSIS (ISN-WCN 2026) - "Treatment was initiated on the day of admission, starting with intravenous methylprednisolone (1000 mg/day for three days), followed by oral prednisolone...Cyclosporine was introduced as adjunctive therapy, and corticosteroids were gradually tapered...The patient has since maintained long-term remission.Results Although FNG is not considered to involve an immunologic mechanism, several reports have described cases without coexisting autoimmune disease that responded favorably to corticosteroids or combined immunosuppressive therapy, such as mycophenolate mofetil...In our case, the patient initially presented with refractory nephrotic syndrome and underwent LDL-A, which led to a mild improvement in serum albumin levels.Conclusion We report a rare case of FNG presenting with nephrotic syndrome that achieved remission through a combination of immunosuppressive therapy and LDL-A. Further accumulation of clinical evidence is needed to clarify the therapeutic efficacy and..."

Dyslipidemia • Glomerulonephritis • Immunology • Lupus Nephritis • Nephrology • Renal Disease • FN1

UNFOLDING THE MYSTERY OF THROMBOTIC MICRO-ANGIOPATHY IN KIDNEY TRANSPLANTATION: ITS INCIDENCE, RISK FACTORS AND CLINICAL OUTCOMES THROUGH BIOPSY PRECISION (ISN-WCN 2026) - "At the time of diagnosis of TMA 58 patients (46%) had Deltacortil+ Azathioprine+ cyclosporine as immunosuppression of choice. Mean Serum Creatinine at the time of diagnosis of TMA is 1.94±0.93, while serum creatinine at 3 months post TMA found to be 2.21±1.67 and at 6 months 2.16±1.62 and after 1 year was 2.37±1.95. 55 patients (43.7%) had complete recovery, 38 (30.2%) showed no response, 15 (11.9%) developed ESRD with mortality in 6 (4.8%) as an outcome 1 year post transplantation.Conclusion Thrombotic Micro-angiopathy occurring after transplant adversely affects graft function and a significant minority lose their graft in one year."

Biopsy • Clinical • Clinical data • Antibody-mediated Rejection • Chronic Kidney Disease • Infectious Disease • Transplantation • KEAP1

LEYDIG CELL HYPERPLASIA PRESENTING AS PRIMARY AMENORRHEA IN A KIDNEY TRANSPLANT PATIENT WITH FRASIER SYNDROME (ISN-WCN 2026) - "Post-transplant, she was maintained on cyclosporine and azathioprine until acute T-cell-mediated rejection in 2023 prompted rituximab and switch to tacrolimus, mycophenolate, and prednisone. Early genetic and pathologic evaluation in transplant recipients presenting with primary amenorrhea is essential to guide prophylactic gonadectomy, optimize hormone replacement, and prevent gonadal malignancy while preserving graft function. Multidisciplinary management—including nephrology, endocrinology, genetics, and psychosocial support—remains critical for long-term outcomes in this rare but clinically significant entity."

Clinical • Cognitive Disorders • Endocrine Disorders • Glomerulonephritis • Lupus Nephritis • Nephrology • Ovarian Cancer • Rare Diseases • Solid Tumor • Transplantation • Turners Syndrome • Wilms Tumor • Women's Health • WT1

PATHOLOGICAL EVALUATION AND TREATMENT STRATEGIES FOR CLINICALLY REFRACTORY CASES OF IGA VASCULITIS NEPHRITIS (ISN-WCN 2026) - "This study aimed to investigate the clinical and pathological characteristics of refractory cases unresponsive to MPT or cyclosporine (CsA), and to explore treatment strategies based on pathological findings and their underlying mechanisms.Methods We retrospectively analyzed 25 pediatric cases diagnosed with IgAV-N (ISKDC histological grade III or higher) via renal biopsy at our institution and affiliated centers. The cases were divided into two groups: a refractory group (n=5), in which remission was achieved only after the introduction of cyclophosphamide (CYP) following failure of MPT and CsA; and a non-refractory group (n=20), in which remission was achieved without CYP...Immunofluorescence staining of biopsy from refractory group revealed proliferating leukocytes (PCNA+CD45+ cells) within the glomeruli, many of which were CD68+ macrophages.Conclusion Although the ISKDC classification is based on the extent of crescent formation, our findings suggest that..."

Clinical • IgA Nephropathy • Nephrology • Vasculitis • CD68 • PCNA • PTPRC

LIMITED DIAGNOSTIC UTILITY OF LIGHT CHAIN AND IGA SUBCLASS STAINING IN IGA-TYPE MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE (ISN-WCN 2026) - "The other patient with suspected IgA1-λ PGNMID responded to repeated steroid pulses plus cyclosporine, achieving partial remission (< 1 g/gCr).Conclusion Light chain restriction in IgA-dominant glomerular deposition is not uncommon but often reflects polyclonal IgA nephropathy rather than MGRS. While KM55 staining for galactose-deficient IgA1 is useful for differentiating IgAN from monoclonal IgA deposition, its negativity or weak reactivity should raise suspicion for IgA-type MGRS. Ultimately, IgA-type MGRS should be diagnosed through an integrated assessment of light chain restriction, IgA subclass predominance, KM55 staining pattern, and clinical course, supported by repeat biopsy and clone-directed evaluation when indicated."

Glomerulonephritis • IgA Nephropathy • Monoclonal Gammopathy • Renal Disease • Vasculitis

REBIOPSY-GUIDED LONG-TERM MANAGEMENT AND IPTACOPAN INTRODUCTION IN A STEROID-DEPENDENT CASE OF C3 GLOMERULOPATHY WITH CYCLOSPORINE NEPHROTOXICITY (ISN-WCN 2026) - "Subsequently, mycophenolate mofetil (MMF 1–1.5 g/day) was added. Iptacopan, an oral factor B inhibitor, reduced proteinuria by ∼40% and normalized complement activity within 12 months in the phase 3 APPEAR-C3G trial, supporting both its mechanistic rationale and clinical applicability in this case. The transition marks a strategic shift toward targeted factor B inhibition aiming for sustained disease control with minimized exposure to conventional immunosuppression."

Clinical • Complement-mediated Rare Disorders • Fibrosis • Glomerulonephritis • Immunology • Nephrology

RIBBON-LIKE ELECTRON-DENSE DEPOSITS IN NELL1-POSITIVE MEMBRANOUS NEPHROPATHY (ISN-WCN 2026) - "The patient was treated with prednisolone (20 mg/day), rituximab (500 mg), and cyclosporine (100 mg/day). However, the patient experienced progressive cognitive decline and died of heart failure 12 months after diagnosis.Conclusion This case demonstrates an extremely rare NELL-1-positive membranous nephropathy with ribbon-like continuous subepithelial deposits throughout the glomerular basement membrane, unlike the typical segmental pattern. This novel morphological variant expands our understanding of NELL-1-positive MN and requires further investigation."

Atherosclerosis • Cardiovascular • Chronic Obstructive Pulmonary Disease • Congestive Heart Failure • Fibrosis • Glomerulonephritis • Heart Failure • Immunology • Lupus Nephritis • Peripheral Arterial Disease • Pulmonary Disease • Renal Disease • Respiratory Diseases • EXT1 • NELL1

CLEAR CELL RENAL CELL CARCINOMA INCIDENTALLY DETECTED ON RENAL BIOPSY IN A PATIENT WITH MEMBRANOUS NEPHROPATHY (ISN-WCN 2026) - "Immunosuppressive therapy with prednisolone and cyclosporine was initiated for MN.Results The patient was diagnosed with MN complicated by RCC...In this patient, direct intervention for RCC was not feasible, and management consisted of immunosuppressive therapy for MN with careful oncologic surveillance. When RCC is incidentally identified in renal biopsy specimens, regular imaging follow-up remains essential even if no mass is initially visible on imaging."

Biopsy • Clinical • Cardiovascular • Clear Cell Renal Cell Carcinoma • CNS Disorders • Dyslipidemia • Epilepsy • Genito-urinary Cancer • Glomerulonephritis • Hypertension • Metabolic Disorders • Oncology • Renal Disease • Solid Tumor

MINIMAL CHANGE DISEASE ASSOCIATED WITH RIBOCICLIB: A NOVEL RENAL COMPLICATION OF CDK4/6 INHIBITOR THERAPY (ISN-WCN 2026) - "The three FDA-approved agents-ribociclib, palbociclib, and abemaciclib-are oral therapies used long-term until disease progression...She was treated with anastrozole and palbociclib, but within two months developed AKI (Cr 1.93 mg/dL) with hypomagnesemia (0.5 mg/dL) and hypocalcemia (6.6 mg/dL), which resolved after discontinuation...Prednisone was then discontinued and cyclosporine initiated, reducing UPCR to 1.01g/g by March 2025, but creatinine rose to 3.19 mg/dL with hypertension, hyperlipidemia, and headaches. Cyclosporine was stopped, and the patient received rituximab, after which UPCR improved to 0.6 g/g by September 2025. Her cancer has remained in remission since the time of ribociclib initiation.Conclusion CDK4/6 inhibitors are increasingly used in hormone receptor–positive breast cancer and can affect kidney function through both functional and structural mechanisms. This is the first case to describe minimal change disease that occurred in association with..."

Atherosclerosis • Back Pain • Breast Cancer • Diabetes • Dyslipidemia • Endocrine Disorders • Glomerulonephritis • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Hypertension • Metabolic Disorders • Musculoskeletal Pain • Solid Tumor • Type 2 Diabetes Mellitus • HER-2 • PGR

SUCCESSFUL USE OF LDL APHERESIS IN CYCLOSPORINE-RESISTANT NEPHROTIC SYNDROME: A CASE REPORT WITH MECHANISTIC INSIGHTS (ISN-WCN 2026) - "The combined clinical and model-based findings suggest that LDL apheresis may exert therapeutic benefits beyond lipid lowering, potentially by modulating CyA pharmacokinetics and enhancing its intracellular delivery. This highlights the broader potential of LDL apheresis as an adjunctive therapy in resistant forms of nephrotic syndrome."

Case report • Clinical • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Glomerulonephritis • Lupus Nephritis • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus